Tag: equity
-
Juno Therapeutics Raises $265 Million in IPO
19 December 2014. Juno Therapeutics, a biotechnology company spun-off from research labs in Seattle and New York, raised some $265 million yesterday in its initial public stock offering. The Seattle enterprise developing cancer therapies that harness the immune system issued 11 million shares of common stock priced at $24.00, and trades on the Nasdaq exchange…
-
Autoimmune Therapy Developer Raises $23M in Early Funds
18 December 2014. Padlock Therapeutics, a biotechnology company creating treatments for diseases where the immune system attacks the body, gained $23 million in its first venture funding round. Financing for the Cambridge, Massachusetts enterprise was led by Atlas Venture, with participation from Index Ventures, MS Ventures, and Johnson & Johnson Development Corporation, the company’s venture…
-
Nanomedicine Developer Secures $7.5M Venture Funds
15 December 2014. Cristal Therapeutics, a developer of medications formulated as nanoscale particles, raised more than €6 million ($7.5 million) in early-stage venture funds. The financing round for the company, based in Maastricht, The Netherlands, was led by Chemelot Ventures, with current seed investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding, and Beheer Innovatiefonds…
-
Merck Buys Antibiotic Maker in $9.5 Billion Deal
8 December 2014. The pharmaceutical company Merck agreed today to acquire Cubist Pharmaceuticals, a developer of antibiotics, in a deal valued at $9.5 billion. Under the agreement Merck will pay Cubist stockholders $102 a share in cash — the stock closed at about $74 a share on Friday — equaling $8.4 billion, as well as…
-
Venture Launched to Reduce Chronic Hospitalizations
10 November 2014. Sentrian, a new enterprise in Aliso Viejo, California, announced its launch today to offer a system combining personalized remote patient monitoring and cloud-based analytics that reduces what it calls preventable hospitalizations. The company also raised $12 million in early-stage venture funds. A spin-off from Singularity University, a Silicon Valley technology training organization and…
-
Biosimilars Developer Lands $85 Million in IPO
7 November 2014. Coherus BioSciences Inc., a company developing medications comparable to brand-name biologic therapies, raised $85 million yesterday in its initial public stock offering. The Redwood City, California company trades on the NASDAQ exchange under the symbol CHRS. Coherus valued its 6,296,300 initial shares at $13.50. The stock opened today at $12.74 a share,…
-
Needleless Delivery Start-Up Lands $11M First-Round Funding
15 October 2014. Portal Instruments Inc., a new enterprise developing needless injections for biologic therapies and other medications, raised $11 million in its first round of venture funding. Financing for the Cambridge, Massachusetts company was led by the Sunrise division of drug maker Sanofi, venture capital company PBJ Capital, and an unnamed medical device manufacturer…
-
Cancer Therapy Biotech Raises $24M in Early Funding
14 October 2014. Raze Therapeutics, a biotechnology company designing cancer therapies that stop mechanisms feeding the growth of cancer cells, raised $24 million in its first round of venture financing. The funding round was led Atlas Venture — that co-founded Raze and provided some of its seed capital — as well as MPM Capital Management,…
-
Experimental Drug Kills Myeloma Cells in Lab, Trial Planned
13 October 2014. Medical researchers at Imperial College London in the U.K. developed an experimental drug that in lab and animal tests kills multiple myeloma cancer cells without the toxic side effects of other cancer drugs. The team led by Imperial medical professor Guido Franzoso published its findings today in the journal Cancer Cell, with…
-
Drug-Error Analytics Service Raises $1M in Early Funding
2 October 2014. MedAware, a company harnessing big-data analytics to prevent erroneous drug prescriptions, raised $1 million in its first round of venture financing. The Ra’anana, Israel enterprise completed the funding round led by OurCrowd, an Israeli crowdfunding investment service, with contributions from GE Ventures. The company is the creation of CEO Gidi Stein, a…